Skip to main content

Table 4 Physicochemical properties of optimal SAHNs and ISHNs. The data are expressed as the mean ± SD (n = 3)

From: Hyaluronan self-agglomerating nanoparticles for non-small cell lung cancer targeting

 

Formulation

Mean diameter (nm)

Polydispersity index (PDI)

Zeta potential (mV)

Encapsulation efficiency (%)a

Drug-loading efficiency (%)b

Drug content

(mg/mL)c

Before lyophilization

SAHNs

89.3 ± 3.31

0.17 ± 0.03

− 31.9 ± 0.32

–

–

–

ISHNs

93.8 ± 4.48

0.19 ± 0.02

− 36.3 ± 0.28

58.3 ± 0.15

25.1 ± 0.09

1.75 ± 0.11

After lyophilization

SAHNs

87.5 ± 4.09

0.20 ± 0.05

− 31.2 ± 0.25

–

–

–

ISHNs

95.2 ± 5.56

0.21 ± 0.03

− 36.6 ± 0.41

57.3 ± 0.08

24.7 ± 0.07

1.72 ± 0.29

  1. SAHNs self-agglomerating hyaluronan nanoparticles, ISHN irinotecan-loaded self-agglomerating hyaluronan nanoparticles
  2. aEncapsulation efficiency (%) = (amount of irinotecan hydrochloride encapsulated in ISHNs/amount of the feed source of irinotecan hydrochloride) × 100%
  3. bDrug-loading efficiency (%) = (amount of irinotecan hydrochloride in ISHNs/amount of the feed source and irinotecan hydrochloride) × 100
  4. cDrug content (mg/mL) = (amount of irinotecan hydrochloride in ISHNs/amount of the feeding material and irinotecan hydrochloride in a 15-mL vial)
Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us